Brief: Bicycle Therapeutics Announces First Patient Dosed In Phase I/II Trial Of Bicycle Tumor-Targeted Immune Cell Agonist Bt7480
04/11/2021 12:56
Nov 4 (Reuters) - Bicycle Therapeutics PLC BCYC.O :
* BICYCLE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE I/II
TRIAL OF BICYCLE® TUMOR-TARGETED IMMUNE CELL AGONIST™ BT7480 IN
PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH NECTIN-4
EXPRESSION
Source text for Eikon: ID:nBw884NBNa
Further company coverage: BCYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary
UK's Bicycle Therapeutics Q3 loss narrows as expenses fall
Bicycle Therapeutics PLC expected to post a loss of 43 cents a share - Earnings Preview
UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses
Bicycle Therapeutics Q1 revenue drops after partnership terminations